latest news releases from the newsroom
Labaton Sucharow LLP
Labaton Sucharow & Rudoff LLP Files Class Action Lawsuit Against Monster Worldwide, Inc. -- MNST
NEW YORK, March 15, 2007 (PRIME NEWSWIRE) -- Labaton Sucharow & Rudoff LLP filed a class action lawsuit on March 15, 2007 in the United States District Court for the Southern District of New York, on behalf of persons who purchased or otherwise acquired publicly traded securities of Monster Worldwide, Inc. ("Monster" or the "Company") (Nasdaq:MNST) between May 6, 2005 and June 9, 2006, inclusive, (the "Class Period"). The lawsuit was filed against Monster and Andrew T. McKelvey, Myron Olesnyckyj and Charles "Lanny" Baker ("Defendants").
Scantek Medical, Inc.
Scantek Medical Enters Into Joint Venture; Scantek Medical to Sell Distribution License
CEDAR KNOLLS, N.J., March 15, 2007 (PRIME NEWSWIRE) -- Scantek Medical, Inc. (Pink Sheets:SKML) announced today that it created a limited liability company, Gibraltar Global Marketing LLC ("Gibraltar"), through which it will engage in a joint venture (the "Joint Venture") with Life Medical Technologies, Inc. ("Life Medical"). Gibraltar was organized to distribute Scantek's BreastCare(tm)/BreastAlert(tm) Differential Temperature Sensor product ("BreastCare") in more than 150 countries throughout the world.
Acura Pharmaceuticals Inc.
Acura Pharmaceuticals, Inc. Reports 2006 Financial Results and Cash Reserves
PALATINE, Ill., March 15, 2007 (PRIME NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCBB:ACUR) today announced a net loss of $6.0 million or $0.08 per common share for calendar year 2006 compared to a net loss of $12.1 million or $0.18 per common share for calendar year 2005. For the quarter ended December 31, 2006 the Company had net income of $3.9 million with a loss of $0.04 per common share after special non-cash deemed dividends (as described below). This compares to a net loss of $7.1 million or $0.04 per common share for the same quarter in 2005.
Acura Pharmaceuticals Inc.
Acura Pharmaceuticals, Inc. Updates OxyADF Tablets Development Program and Results of Study AP-ADF-102
PALATINE, Ill., March 15, 2007 (PRIME NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCBB:ACUR) today announced results of Study AP-ADF-102 ("Study 102"), a phase II clinical trial for OxyADF (oxycodone HCl and niacin) Tablets, the Company's lead product candidate incorporating its proprietary Aversion(r) (abuse deterrent) Technology. OxyADF Tablets are being developed pursuant to an investigational new drug application ("IND") on file with the U.S. Food and Drug Administration ("FDA") with an intended indication for treatment of moderate to moderately severe pain. The Company also provided a status update on the overall OxyADF Tablets development program and its proprietary Aversion(r) (abuse deterrent) Technology.